Medtronic (NYSE:MDT) announced today that it received an FDA warning letter after an inspection of its Diabetes Business.
The company received the letter on Dec. 9 for its Northridge, California facility — the Medtronic Diabetes Business headquarters — following an inspection that concluded in July 2021.
Shares of MDT were down 6.3% at $104.62 per share in early-morning trading today on the back of the news of the FDA letter. The company’s shares finished the day down 6% in total at $104.94 per share.
Get the full story at our sister site, Drug Delivery Business News.
